UBS AM
NGM

UBS AM’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

UBS AM’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-31,431
Closed -$128K – 2710
2023
Q2 		$128K Hold
31,431
– – ﹤0.01% 2618
2023
Q1 		$128K Hold
31,431
– – ﹤0.01% 2618
2022
Q4 		$158K Buy
31,431
+664
+2% +$4.16K ﹤0.01% 2470
2022
Q3 		$402K Sell
30,767
-3,896
-11% -$59K ﹤0.01% 2422
2022
Q2 		$444K Buy
34,663
+16,034
+86% +$222K ﹤0.01% 2353
2022
Q1 		$284K Hold
18,629
– – ﹤0.01% 2612
2021
Q4 		$330K Sell
18,629
-6,316
-25% -$121K ﹤0.01% 2660
2021
Q3 		$524K Buy
24,945
+14,754
+145% +$325K ﹤0.01% 2482
2021
Q2 		$201K Buy
+10,191
New +$239K ﹤0.01% 2709

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS AM's NGM Position: Q3 2023 in Review

UBS AM sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q3 2023, closing a stake of 31,431 shares — an estimated $128K sold.

UBS AM first reported a position in NGM in Q2 2021 and held it in 9 quarters. The position peaked at $524K in Q3 2021. 94 funds tracked by Wall St. Rank hold NGM as of Q3 2023.

  • UBS AM reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • UBS AM sold 31,431 NGM Biopharmaceuticals, Inc. Common Stock shares in Q3 2023, an estimated $128K.
  • UBS AM first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 9 quarters.
  • UBS AM's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $524K in Q3 2021.
  • 94 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2023.

Based on UBS AM's 13F filing for Q3 2023, filed 13 Nov 2023.